GENinCode (LON:GENI) Reaches New 52-Week Low – Here’s Why

GENinCode Plc (LON:GENI) shares reached a new 52-week low during mid-day trading on Monday. The company traded as low as GBX 0.56 and last traded at GBX 0.64, with a volume of 1,374,834 shares. The stock had previously closed at GBX 0.64.

GENinCode Trading Up 3.7%

The company has a market capitalization of £5.27 million, a PE ratio of -0.55 and a beta of 0.59. The company has a current ratio of 2.22, a quick ratio of 15.88 and a debt-to-equity ratio of 4.75. The stock has a fifty day moving average of GBX 0.83 and a two-hundred day moving average of GBX 0.94.

GENinCode (LON:GENI) last posted its quarterly earnings results on Tuesday, September 29th. The company reported GBX (0.38) earnings per share for the quarter. GENinCode had a negative return on equity of 481.34% and a negative net margin of 202.42%. As a group, sell-side analysts anticipate that GENinCode Plc will post -7.13 earnings per share for the current fiscal year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.